GlassScriptPhysician profile
Eugene M Azuma
NPI 1639101454
$14,343.94
in general payments reported to CMS, 2019-2025
13 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 98% of General Practice (Dentist) providers received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,798 · 2020: $319 · 2021: $2,909 · 2022: $936 · 2023: $3,244 · 2024: $2,496 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613 · Education: $3,066 · Gift: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.66 |
| Education | $3,065.69 |
| Gift | $704.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Sirona INC | $5,773.14 | 2019-2025 | Waveone Gold Conform Fit, Suresmile, Cerec Tessera |
| Patterson Companies, INC. | $4,589.82 | 2019-2025 | |
| A-Dec, INC. | $1,096.00 | 2019 | |
| Ultradent Products INC | $951.13 | 2021-2025 | Opalescence |
| Sirona Dental, INC. | $750.00 | 2019 | |
| Dentsply LLC | $300.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $240.36 | 2021-2022 | |
| Biohorizons Implant Systems INC. | $223.32 | 2019-2024 | Biohorizons |
| Envista Holdings Corporation | $193.86 | 2024-2025 | Optibond Fl, Nexus Rmgi, Harmonize |
| Nobel Biocare USA | $128.76 | 2023 | Nobelactive |
| Hu-Friedy Mfg. Co., LLC | $40.00 | 2020 | |
| Kerr Corporation | $38.81 | 2023 | Maxcem Elite |
| Voco America INC. | $18.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Azuma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.